Hoth Therapeutics' GDNF Therapy Outperforms Semaglutide in Preclinical Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy HOTH?
Source: Newsfilter
- Significant Weight Loss: In female mice on a high-fat Western diet, GDNF reduced weight gain by 10-15%, unlike semaglutide, indicating GDNF's substantial potential in obesity treatment and offering a new therapeutic option.
- Enhanced Glucose Metabolism: GDNF fully normalized fasting glucose levels and outperformed semaglutide in glucose challenge responses, demonstrating broad metabolic benefits, particularly in female models.
- Liver and Adipose Tissue Health: GDNF reduced liver weight by 20-30% and prevented adipose tissue accumulation in females, surpassing semaglutide's effects, highlighting its promise in addressing obesity-related fatty liver disease.
- Study Design and Future Plans: Conducted at the Srinivasan Lab over 12 weeks, Hoth plans to accelerate GDNF towards IND-enabling studies, targeting clinical trials in 2027, further advancing its application in the $200 billion obesity market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HOTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HOTH
About HOTH
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hoth Therapeutics Integrates AI to Support Rare Cancer Therapy Progression
- AI Integration: Hoth Therapeutics has announced the integration of OpenAI's API into the HT-KIT development workflow to support IND preparation and preclinical data analysis, thereby accelerating the advancement of treatments for rare KIT-driven cancers.
- Significant Efficacy: HT-KIT achieved over 80% suppression of KIT mRNA and protein in both in vitro and in vivo models, demonstrating its potential efficacy in treating systemic mastocytosis and gastrointestinal stromal tumors, highlighting its significant promise in addressing rare cancers.
- Favorable Tolerability: No dose-limiting toxicities were observed in early studies, indicating the safety of HT-KIT for clinical applications and laying a solid foundation for subsequent clinical trials.
- Bioanalytical Readiness: GLP-validated bioanalytical methods have been completed to support pharmacokinetic, biodistribution, and exposure-response analyses for IND, ensuring HT-KIT's smooth transition into clinical trial phases.
See More
Hoth Therapeutics Integrates AI for IND Preparation and Phase 1 Progression
- AI Integration: Hoth Therapeutics has announced the integration of OpenAI's API into the HT-KIT development workflow to support IND preparation for rare KIT-driven cancers, enhancing data analysis and molecular modeling efficiency, thereby accelerating preclinical research progress.
- IND Strategy Advancement: CEO Robb Knie stated that the application of AI not only optimizes the HT-KIT development process but also prepares necessary regulatory documentation for the upcoming IND submission, marking a significant step towards Phase 1 clinical trials.
- Patient-Centric R&D: Hoth Therapeutics is dedicated to developing innovative therapies, leveraging AI technology to improve patient quality of life, indicating the company's crucial role in early-stage drug development, which may attract more investor interest.
- Market Potential Outlook: With the increasing demand for treatments for rare cancers, Hoth's AI integration strategy not only enhances R&D efficiency but also positions the company favorably in the future market, driving long-term growth.
See More
Hoth Therapeutics Utilizes OpenAI API to Enhance Progress of Orphan HT-KIT Oncology Initiative
Company Overview: Hoth Therapeutics is advancing its development of a new program focused on oncology, specifically targeting orphan diseases.
Technology Utilization: The company is deploying its proprietary platform, OpenAI API, to enhance the research and development processes within its oncology program.
See More
Hoth Therapeutics Deploys OpenAI API to Support HT-KIT Development
- Technology Integration: Hoth Therapeutics announced the integration of OpenAI API into the HT-KIT development workflow to support IND-enabling development for rare and aggressive KIT-driven cancers, enhancing data analysis and molecular modeling efficiency.
- Preclinical Results: HT-KIT achieved over 80% reduction of KIT mRNA/protein in both in vitro and in vivo models, with no dose-limiting toxicities observed, demonstrating its potential in systemic mastocytosis and gastrointestinal stromal tumors.
- Tumor Reduction Effects: Statistically significant tumor volume reduction was observed by Day 8 in xenograft models, accompanied by apoptotic signaling consistent with KIT pathway knockdown, indicating substantial therapeutic efficacy.
- Regulatory Readiness: Hoth Therapeutics has completed GLP-validated bioanalytical methods to support pharmacokinetic, biodistribution, and exposure-response analyses for IND, with HT-KIT advancing toward IND submission and Phase 1 clinical evaluation, having received Orphan Drug Designation.
See More
Hoth Therapeutics Expands CLEER-001 Clinical Trial Amid Rising Patient Demand
- Trial Expansion: Hoth Therapeutics announces the expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis Clinical Research in Miami, Florida, reflecting surging patient demand and strong interest in the promising early clinical results of HT-001.
- Rising Patient Demand: Approximately 200,000 Americans undergo EGFR inhibitor therapy annually, facing severe skin toxicities that can lead one-third to reduce or discontinue chemotherapy, highlighting the urgent need for HT-001 as a potential solution.
- Accelerated Enrollment: The addition of Regis Clinical Research will expedite patient enrollment, enabling Hoth to achieve a complete data set more quickly and reach critical regulatory milestones, enhancing its competitive position in cancer treatment.
- Significant Market Potential: With positive interim data generating increased interest from physicians and patients, Hoth plans to build robust infrastructure to meet growing demand, potentially transforming treatment paradigms in cancer care.
See More
Hoth Secures Patent to Enhance Immunology IP Portfolio
- Patent Approval: Hoth Therapeutics announced that the USPTO has issued a Notice of Allowance for the patent on 'Exon Skipping of FC-Epsilon-RI-Beta and MS4A6A in the Treatment of Allergic Diseases,' marking a significant enhancement of the company's immunology intellectual property.
- Innovative Treatment Strategy: The patent protects a novel dual-mechanism approach targeting key regulators of allergic and inflammatory responses, positioning Hoth at the forefront of next-generation immunomodulatory therapies, which could reshape the global allergy and immunology market.
- Management Commentary: CEO Robb Knie stated that receiving this patent is an important milestone in building Hoth's intellectual property portfolio, further expanding the company's strategy for developing differentiated therapies for immune-driven diseases and enhancing long-term shareholder value.
- Market Outlook: By focusing on upstream drivers of allergic inflammation rather than merely treating downstream symptoms, this strategy not only strengthens Hoth's competitive position but also opens new growth opportunities in the rapidly evolving biopharmaceutical market.
See More
Hoth Therapeutics Integrates AI to Support Rare Cancer Therapy Progression
- AI Integration: Hoth Therapeutics has announced the integration of OpenAI's API into the HT-KIT development workflow to support IND preparation and preclinical data analysis, thereby accelerating the advancement of treatments for rare KIT-driven cancers.
- Significant Efficacy: HT-KIT achieved over 80% suppression of KIT mRNA and protein in both in vitro and in vivo models, demonstrating its potential efficacy in treating systemic mastocytosis and gastrointestinal stromal tumors, highlighting its significant promise in addressing rare cancers.
- Favorable Tolerability: No dose-limiting toxicities were observed in early studies, indicating the safety of HT-KIT for clinical applications and laying a solid foundation for subsequent clinical trials.
- Bioanalytical Readiness: GLP-validated bioanalytical methods have been completed to support pharmacokinetic, biodistribution, and exposure-response analyses for IND, ensuring HT-KIT's smooth transition into clinical trial phases.
See More
Hoth Therapeutics Integrates AI for IND Preparation and Phase 1 Progression
- AI Integration: Hoth Therapeutics has announced the integration of OpenAI's API into the HT-KIT development workflow to support IND preparation for rare KIT-driven cancers, enhancing data analysis and molecular modeling efficiency, thereby accelerating preclinical research progress.
- IND Strategy Advancement: CEO Robb Knie stated that the application of AI not only optimizes the HT-KIT development process but also prepares necessary regulatory documentation for the upcoming IND submission, marking a significant step towards Phase 1 clinical trials.
- Patient-Centric R&D: Hoth Therapeutics is dedicated to developing innovative therapies, leveraging AI technology to improve patient quality of life, indicating the company's crucial role in early-stage drug development, which may attract more investor interest.
- Market Potential Outlook: With the increasing demand for treatments for rare cancers, Hoth's AI integration strategy not only enhances R&D efficiency but also positions the company favorably in the future market, driving long-term growth.
See More
Hoth Therapeutics Utilizes OpenAI API to Enhance Progress of Orphan HT-KIT Oncology Initiative
Company Overview: Hoth Therapeutics is advancing its development of a new program focused on oncology, specifically targeting orphan diseases.
Technology Utilization: The company is deploying its proprietary platform, OpenAI API, to enhance the research and development processes within its oncology program.
See More
Hoth Therapeutics Deploys OpenAI API to Support HT-KIT Development
- Technology Integration: Hoth Therapeutics announced the integration of OpenAI API into the HT-KIT development workflow to support IND-enabling development for rare and aggressive KIT-driven cancers, enhancing data analysis and molecular modeling efficiency.
- Preclinical Results: HT-KIT achieved over 80% reduction of KIT mRNA/protein in both in vitro and in vivo models, with no dose-limiting toxicities observed, demonstrating its potential in systemic mastocytosis and gastrointestinal stromal tumors.
- Tumor Reduction Effects: Statistically significant tumor volume reduction was observed by Day 8 in xenograft models, accompanied by apoptotic signaling consistent with KIT pathway knockdown, indicating substantial therapeutic efficacy.
- Regulatory Readiness: Hoth Therapeutics has completed GLP-validated bioanalytical methods to support pharmacokinetic, biodistribution, and exposure-response analyses for IND, with HT-KIT advancing toward IND submission and Phase 1 clinical evaluation, having received Orphan Drug Designation.
See More
Hoth Therapeutics Expands CLEER-001 Clinical Trial Amid Rising Patient Demand
- Trial Expansion: Hoth Therapeutics announces the expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis Clinical Research in Miami, Florida, reflecting surging patient demand and strong interest in the promising early clinical results of HT-001.
- Rising Patient Demand: Approximately 200,000 Americans undergo EGFR inhibitor therapy annually, facing severe skin toxicities that can lead one-third to reduce or discontinue chemotherapy, highlighting the urgent need for HT-001 as a potential solution.
- Accelerated Enrollment: The addition of Regis Clinical Research will expedite patient enrollment, enabling Hoth to achieve a complete data set more quickly and reach critical regulatory milestones, enhancing its competitive position in cancer treatment.
- Significant Market Potential: With positive interim data generating increased interest from physicians and patients, Hoth plans to build robust infrastructure to meet growing demand, potentially transforming treatment paradigms in cancer care.
See More
Hoth Secures Patent to Enhance Immunology IP Portfolio
- Patent Approval: Hoth Therapeutics announced that the USPTO has issued a Notice of Allowance for the patent on 'Exon Skipping of FC-Epsilon-RI-Beta and MS4A6A in the Treatment of Allergic Diseases,' marking a significant enhancement of the company's immunology intellectual property.
- Innovative Treatment Strategy: The patent protects a novel dual-mechanism approach targeting key regulators of allergic and inflammatory responses, positioning Hoth at the forefront of next-generation immunomodulatory therapies, which could reshape the global allergy and immunology market.
- Management Commentary: CEO Robb Knie stated that receiving this patent is an important milestone in building Hoth's intellectual property portfolio, further expanding the company's strategy for developing differentiated therapies for immune-driven diseases and enhancing long-term shareholder value.
- Market Outlook: By focusing on upstream drivers of allergic inflammation rather than merely treating downstream symptoms, this strategy not only strengthens Hoth's competitive position but also opens new growth opportunities in the rapidly evolving biopharmaceutical market.
See More
